PHARMACOKINETICS OF MAGNESIUM ISOGLYCYRRHI-ZINATE AFTER SINGLE INTRAVENOUS DOSE IN HEALTHY VOLUNTEERS

Objective To study the pharmacokinetics of intravenous magnesium isoglycyrrhizinate injection in health volunteers with HPLC-UV. Methods Single doses of 2OOmg magnesium isoglycyrrhizinate were administrated to 10 health volunteers by i. v. infusion. The concentrations of magnesium isoglycyrrhizinate in plasma were assayed by HPLC-UV method. The pharmacokinetic parameters of magnesium isoglycyrrhizinate injection were calculated by program 3P87. Results The main pharmacokinetic parameters of intravenous magnesium isoglycyrrhizinate were as follows： cmax （ 67. 58 ± 8. 84 ） mg/L, T1/2α （ 1.46 ± 0. 35 ） h, T1/2β （ 23. 95 ± 4. 72 ） h, Vd （ 2. 921 ± 0. 382） L, CL （0. 186 ±0. 048） L/h,k10（0. 064 ±0. 016） h^-1, AUC0-T（1015.29 ±225. 14） mg·h^-1·L^-1 ,respectively. Conclusion We have successfully used the analytical method for magnesium isoglycyrrhizinate to study its pharmacokinetical properties of health volunteers after i. v. infusion. The method is found to be simple, accurate, stable and sensitive for application in clinical pharmacokinetics study. The concentration-time plot was fitted to a two-compartment open model with first-order elimination.

Effects of co-administraton of neferine and doxorubicin on the pharmacokinetics of doxorubicin

Doxorubicin is one of the anthracycline anti-neoplastic drugs widely used to treat leukemia, liver, breast, and ovarian cancers and other solid tumors. However, its clinical applications have been limited by its serious cardio-cytotoxic effects. The aim of this study was to investigate the effect of neferine, a bisbenzylisoquinoline alkaloid extracted from the green embryo in the mature lotus seed, on the pharmacokinetics of doxorubicin. The levels of doxorubicin in plasma and tissues were measured using the high performance liquid chromatography（HPLC） method. The chromatographic separation was completed on a reversed-phase C18 column using acetonitrile–phosphate buffer（30：70, v/v） as the mobile phase at a flow rate of 1 mL /min and ultraviolet detection wave length was set at 233 nm. The pharmacokinetic study found that the co-administration of neferine and doxorubicin significantly affected the pharmacokinetics of doxorubicin. There were evident changes in area under the curve（AUC）, clearance（CL） and t1/2β in group of pretreatment neferine as compared with those in group treated with doxorubicin alone. Tissue distribution analysis showed that the concentrations of doxorubicin distributed to heart, liver and kidney were statistically significant higher in group of pretreatment with neferine plus doxorubicin than those in the doxorubicin alone-group at 0.5 h and 2 h after drug administration, respectively. While the doxorubicin concentrations in spleen and lung drug were slightly increased in the group of pretreatment with neferine plus doxorubicin as compared to that of group of doxorubicin alone, the difference between two groups were not statistically significant. Therefore, the dose of doxorubicin needs to be taken into consideration when it is administrated in combination with neferine.